Who
Edward Neugeboren
Director
Company insider
Files Form 4 as: Director, Grace Therapeutics; Director, Matinas Biopharma Holdings; Director, Elite Pharmaceuticals Inc /de/.
In numbers
- Trades disclosed
- 9
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 31 Dec 2005
- Last trade
- 17 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 21 Sep 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,200 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,200 at $0.00 | filing |
| 8 Jan 2026filed 12 Jan 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 8 Jan 2026filed 12 Jan 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 9 May 2025filed 13 May 2025 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,600 at $0.00 | filing |
| 19 Dec 2023filed 20 Dec 2023 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 31 Dec 2005filed 27 Mar 2006 | Elite Pharmaceuticals Inc /de/option or derivative | SEC FORM 4 Code A | $9,1473,049 at $3.00 | filing |
| 31 Dec 2005filed 27 Mar 2006 | Elite Pharmaceuticals Inc /de/ | SEC FORM 4 Code F | $16K10,163 at $1.54 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.